COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ghrelin Levels in Pancreatic Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00225745
Recruitment Status : Completed
First Posted : September 26, 2005
Last Update Posted : October 14, 2015
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

Brief Summary:
The primary outcome measure for this study is plasma ghrelin level.

Condition or disease Intervention/treatment
Pancreatic Cancer Procedure: Blood draw

Detailed Description:

The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are:

  • Patients with cachexia versus patients without cachexia
  • Patients with cachexia versus healthy controls

Layout table for study information
Study Type : Observational
Actual Enrollment : 72 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer
Study Start Date : April 2004
Actual Primary Completion Date : October 2013
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Pancreatic cancer patients
Procedure: Blood draw
One blood draw prior to first treatment

Healthy controls
Procedure: Blood draw
One blood draw prior to first treatment

Primary Outcome Measures :
  1. To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls [ Time Frame: prior to treatment ]

Secondary Outcome Measures :
  1. To investigate the role of ghrelin in pathophysiology of cancer cachexia [ Time Frame: prior to treatment ]
  2. To generate hypotheses for future studies and treatment based on the findings [ Time Frame: prior to treatment ]

Biospecimen Retention:   Samples Without DNA
Whole Blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pancreatic cancer patients who have not received treatment. Healthy age-matched controls.

Inclusion Criteria:

  • Histological or cytological proof of pancreatic adenocarcinoma
  • The control are will include healthy age-matched patients without cancer
  • The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
  • Patients must have recovered from any major infections and/or surgical procedures

Exclusion Criteria:

  • Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
  • Patients on appetite stimulant and those receiving total parenteral nutrition
  • Patients who have undergone gastrectomy or those who have gastric ulcers
  • Patients receiving active chemotherapy
  • No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00225745

Layout table for location information
United States, New Hampshire
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Layout table for investigator information
Principal Investigator: J Marc Pipas, MD Dartmouth-Hitchcock Medical Center
Layout table for additonal information
Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT00225745    
Other Study ID Numbers: DMS 0405
First Posted: September 26, 2005    Key Record Dates
Last Update Posted: October 14, 2015
Last Verified: August 2015
Keywords provided by Dartmouth-Hitchcock Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases